Qiagen N.V. · NYSE:QGEN
Qiagen — Investor Presentation (November 2023)
79 slides from Qiagen's investor presentation, November 2023
Slide 1: Investor resource book November 2023
Making improvements in life possible Investor resource book November 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: Table of Contents
Table of Contents About QIAGEN 4 QIAGEN at a glance 5 Business areas 16 Strategy 18 Global presence 20 Debt information 24 Capital allocation 25 Why invest 26 Product portfolios 27 Sample technologies 29 Diagnostic solutions 34 PCR / Nucleic acid amplification 50 Genomics / NGS 58 Sustainability 66
Slide 4: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Investor Resource Book 4
Slide 5: QIAGEN at a glance
QIAGEN at a glance A global company with scale ~45% $2.1 Americas billion Sales ~35% (2022 (2022) EMEA sales) ~20% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~6,200 employees known as QIAGENers ~ 88% 12% 50% 50% ~ ~ ~ Consumables and related revenues Instruments Molecul
Slide 6: QIAGEN solutions are used across the world by researchers
QIAGEN solutions are used across the world by researchers - from young scientists to Nobel laureates - and clinical testing labs Investor Resource Book 6
Slide 7: More than 3 billion samples have been processed
More than 3 billion samples have been processed using QIAGEN sample preparation kits Dr. Darren Chooneea Research Scientist, London Natural History Museum Uses QIAGEN’s PowerSoil Pro Kit to explore the evolution of microorganisms as they adapted to changing environmental conditions and identify the
Slide 8: More than 100 million patients screened with latent TB test
More than 100 million patients have been screened with QIAGEN’s latent TB test Dr. Kiyoyasu Fukushima Japan Red Cross Nagasaki Genbaku Isahaya Hospital Employs QuantiFERON TB Plus for latent tuberculosis detection to ultimately reduce Japan‘s high infection rate Investor Resource Book 8
Slide 9: More than 4 million samples processed with NGS kits
More than 4 million samples have been processed with QIAGEN’s NGS kits Asha Palat and Brandon Mistretta University of Houston’s Department of Biology and Biochemistry Use QIAGEN’s QIAseq FastSelect RNA Removal Kits with next-generation sequencing (NGS) to develop more effective and more humane cance
Slide 10: Developing companion diagnostics with pharma companies
QIAGEN is developing companion diagnostics with over 25 Pharma companies Dr. Philippe Taniere Consultant histopathologist Queen Elizabeth Hospital Birmingham Relies on QIAGEN’s standardized, regulatory- approved tests for KRAS, BRAF and EGFR to break the cellular code of cancer and find the right tr
Slide 11: Every 10 seconds a crime scene sample is analyzed
Every 10 seconds a crime scene sample is analyzed with QIAGEN kits Rachel Oefelein Chief Scientific Officer at DNA Labs International Helping to bring closure to victims and their families by using QIAGEN’s forensic genetic genealogy tools to enable identification of assailants by matching genetic r
Slide 12: Innovative instrument portfolio tackles molecular applications
QIAGEN’s innovative instrument portfolio tackles a variety of molecular applications Dr. Johanna Andersson-Assarsson University of Gothenburg Uses QIAGEN’s QIAcuity digital PCR platform to identify obesity gene variations that could help in the development of new therapies Investor Resource Book 12
Slide 13: QIAGEN products are known for the highest quality
QIAGEN products are known for the highest quality Investing in R&D and best-in-class manufacturing is a top priority Investor Resource Book 13
Slide 14: Providing Sample to Insight solutions
Providing Sample to Insight solutions to uncover molecular insights faster, better and more efficiently Sample technologies Assay technologies Discovery research Advancing understanding of life Pharma Faster and better drug R&D Clinical diagnostics Sample to Insight solutions Accurate disease diagno
Slide 15: Helping over 500,000 customers unlock molecular insights
We are helping over 500,000 customers to unlock molecular insights Investor Resource Book 15
Slide 16: Life sciences: Working to enable scientific advancements
Life sciences: Working to enable scientific advancements QIAGEN value Academic research 2022 sales ~$1 billion Pharma development Recognized innovator supporting scientific breakthroughs Able to translate innovations Applied testing into commercial products ~$5 billion addressable market Selected QI
Slide 17: Molecular Diagnostics: Helping to improve outcomes in healthcare
Molecular Diagnostics: Helping to improve outcomes in healthcare QIAGEN value Immune response 2022 sales ~$1.1 billion Infectious diseases Addressing testing areas with high or growing demand Strong automation portfolio Oncology with multi-year assay menu expansion underway ~$6 billion addressable m
Slide 18: Our Strategy: Leveraging a strong core portfolio to drive Pillars of Growth
Our Strategy: Leveraging a strong core portfolio to drive Pillars of Growth Expanding on solid leadership Early commercialization phases with strong growth potential Sample QuantiFERON QIAstat-Dx NeuMoDx QIAcuity technologies Leading immune Syndromic testing with Differentiated microfluidic Novel mi
Slide 19: We employ ~6,200 passionate QIAGENers
We employ ~6,200 passionate QIAGENers around the world from diverse backgrounds and locations Investor Resource Book 19
Slide 20: Our strong global presence serves developed and emerging markets
Our strong global presence serves both developed and emerging markets >30 Our global Direct sales in and regional headquarters: Venlo Netherlands Germantown Global HQ countries Maryland Americas HQ Hilden Germany EMEA HQ Shanghai China HQ Singapore >170 Shipping product to Asia-Pacific HQ countries
Slide 21: FY 2022: +14% CER growth in non-COVID product groups
FY 2022: +14% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -5% -5% (+0% CER) (+0% CER) $2,252 $2,252 $2,142 $2,142 851 Sample -1% CER 797 technologies Non-COVID 1,547 product groups 1,672 +14% CER Diag
Slide 22: Outlook: Q4 and FY 2023
Outlook: Q4 and FY 2023 Q4 2023 outlook FY 2023 outlook (As of October 30, 2023) Net sales >$500 million CER >$1.97 billion CER Anticipated currency impact Neutral FX impact ~1 percentage point headwind Adjusted diluted EPS >$0.53 CER >$2.07 CER Anticipated currency impact Neutral FX impact At least
Slide 23: FY 2022: Leveraging strong cash flow to build sustainable growth
FY 2022: Leveraging strong cash flow to build sustainable growth Operating cash flow Free cash flow (In $ millions) (In $ millions) Targeted investments into five pillars + 12% High level of R&D investments into menu + 30% expansion for QIAstat-Dx, NeuMoDx and QIAcuity $715 $586 586 $639 Proactively
Slide 24: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of September 30, 2023 Maturities of debt instruments (In $ millions) $1.51 billion $1.02 billion Convertible Bonds Schuldschein Convertible Cash and 117 Bonds short-term 2024 investments 2027 601 612 101 112 $491 million Net de
Slide 25: Capital allocation: Strong balance sheet to create greater value
Capital allocation: Strong balance sheet to create greater value Investing in growth Healthy cash flow and leverage ratio trends $ Expanding test menus and millions manufacturing capacity, 800 1.6x especially in the five pillars 700 1.5x 1.4x 600 Enhance value with M&A 500 Ongoing disciplined approa
Slide 26: Why invest: Well-diversified business spanning attractive markets
Why invest: Well-diversified business spanning attractive markets Diversified Broad Highly customer base geographic reach recurring revenues Well-balanced leadership in ~6,200 QIAGENers ensuring Growing installed base Life Sciences and access to attractive markets with generating demand for Molecula
Slide 27: QIAGEN product portfolios
QIAGEN product portfolios
Slide 28: Sales reporting: Product groups
Sales reporting: Product groups QIAGEN Growth Pillars product groups Sample technologies(1) QIAcuity digital PCR QIAstat-Dx NeuMoDx QuantiFERON Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control including QIAsymphony
Slide 29: Sample technologies
Sample technologies Customers Sample collection, stabilization Manual sample preparation and storage solutions Life Sciences Academic Pharma Applied testing Molecular Diagnostics Automated sample preparation Quality control instruments Investor Resource Book 29
Slide 30: The first step in virtually any molecular biology laboratory process
The first step in virtually any molecular Sample technologies biology laboratory process QIAGEN holds leading products in the vast majority of applications mRNA microRNA Total RNA from FFPE tissue Gel extraction Post-reaction cleanup Up to 60% Total RNA from whole (i.e. PCR, enzyme market share in s
Slide 31: Our Sample technologies are the foundation of QIAGEN
Our Sample technologies are the foundation of QIAGEN Sample technologies A portfolio that has grown to address the complete spectrum of processing biological samples Selected biological samples Applications Tissue Stool Input demands Processing Target analytes Cloning qPCR / dPCR Cells Saliva Low /
Slide 32: Building on Sample Technologies solid leadership
Building on Sample Technologies solid leadership Sample technologies Upgrading key automation platforms Comprehensive QIAcube Connect QIAsymphony Boost consumables portfolio EZ2 Connect Launched 2019 Launched 2021 In development Over 300 kits • Any sample format Add photo • Any analyte for QS (DNA,
Slide 33: SPOTLIGHT: QIAsymphony – Flagship platform for sample processing
SPOTLIGHT: QIAsymphony – Sample technologies Flagship platform for sample processing Off-the-shelf solutions and customizable protocols to fit wide range of laboratory needs Front-end automation solution for molecular testing Regionalization strategy • US: Focus on sample technologies • Rest-of-worl
Slide 34: Diagnostic solutions
Diagnostic solutions Customers Immune Response Infectious diseases Molecular Diagnostics Women’s Health Oncology and Precision Medicine Investor Resource Book 34
Slide 35: Immune Response: Best-in-class IGRA test for latent tuberculosis
Immune Response: Best-in-class IGRA Diagnostic solutions test for latent tuberculosis What is QuantiFERON? Latent TB testing market QuantiFERON-TB Gold Plus (QFT-Plus) is a simple blood test that aids in the detection >$1 QIAGEN of Mycobacterium tuberculosis, the bacteria which causes tuberculosis (
Slide 36: A growing market demand for modern latent TB testing
A growing market demand for Diagnostic solutions modern latent TB testing What is the difference between latent TB ~70 million latent TB tests per year across the world and active TB? Latent TB infection (LTBI) can persist for weeks, months or North America EMEA Japan years before developing into ac
Slide 37: QuantiFERON offers fully automated workflows
QuantiFERON offers fully automated workflows Diagnostic solutions for low and high throughput testing Enabling hands-free processing of QFT-TB Gold Plus Strong best-in-class High performing Excellent Wide menu: assay: automation: Embedded in market position QFT TB Gold Plus DiaSorin, DiaSorin menu (
Slide 38: QuantiFERON Lyme: Combination of tests allowing a new level of detection
QuantiFERON Lyme: Combination of Diagnostic solutions tests allowing a new level of detection CE-IVD test launched in 2021 FDA approval pending (submitted Dec 2022) Rising occurrence of Lyme disease 40,000 Confirmed cases Potential testing market Europe ~35,000 per year ~12-14 million tests per year
Slide 39: Infectious diseases: New generation of PCR technology for urgent needs
Infectious diseases: New generation Diagnostic solutions of PCR technology for urgent needs Core / Hospital laboratories Near-patient clinical laboratories Hospital and Community hospitals and reference lab networks reference lab “outreach” centers Market opportunity Requirements: Requirements: Mark
Slide 40: QIAstat-Dx: Capturing opportunities in syndromic testing
QIAstat-Dx: Capturing Diagnostic solutions opportunities in the rapidly growing market of syndromic testing What is syndromic testing? Syndromic testing is a new approach to molecular diagnostic testing which uses a single test to look for multiple viral, bacterial or fungal infections. Sets of comm
Slide 41: QIAstat-Dx: Reliable, fast and cost-effective diagnosis
QIAstat-Dx: Reliable, fast and cost-effective Diagnostic solutions diagnosis of complex syndromes Unrivaled ease-of-use Liquid / solid sample input Dry swab sample input Self- contained cartridge Real-time PCR reaction chambers Analytical modules Operational module • Small footprint with More than a
Slide 42: QIAstat-Dx: Expanding menu in U.S. and Europe
QIAstat-Dx: Expanding menu Diagnostic solutions in U.S. and Europe Growing test menu Broadening the addressable market with QIAstat-Dx Rise QIAstat-Dx test menu CE-IVD FDA Gastrointestinal Respiratory SARS CoV-2 Small hospitals Medium-sized hospitals National reference labs, Public health labs Regio
Slide 43: QIAstat-Dx: Novel syndromic testing system delivering unique value
QIAstat-Dx: Diagnostic solutions Novel syndromic testing system delivering unique value QIAstat-Dx (4 scalable slots QIAstat-Dx - Rise Biofire FilmArray Biofire Torch Luminex ePlex Genmark Verigene used for (1 slot) (12 slots) (12 slots) (1 slot) comparison) Throughput (in 8 hours) 28 56 9 108 60 4
Slide 44: NeuMoDx: New generation of integrated PCR testing
NeuMoDx: New generation of integrated PCR testing >300 NeuMoDx CE-IVD test menu Offering the ease of clinical chemistry for cumulative molecular testing placements (1) HBV Blood-borne HCV viruses HIV CMV Easier Faster More versatile EBV 2.0 Simple three-step First results in ~1 hour Laboratory-devel
Slide 45: NeuMoDx: Unique integrated PCR platform in >$3 billion market
NeuMoDx: A unique integrated PCR testing Diagnostic solutions platform in >$3 billion market opportunity Roche Cobas Hologic Hologic 6800 Roche Cobas Beckman Veris NeuMoDx 288 NeuMoDx 96 Abott Alinity M Panther Panther Fusion (+ Omni LDT 8800 (Discontinued) channel) Volume in '00,000s cm3 38 16 18 2
Slide 46: Oncology and Precision Medicine: QIAGEN as a partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice CDx and LDT Market >25 >$1.1 billion annually ~15% CAGR pharma partnerships Currently mostly LDT’s Day One Lab Readiness program Program designed to further accelerate the access of cancer patients to QIAGEN’s compan
Slide 47: Oncology and Precision Medicine: QIAGEN as a partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice QIAGEN molecular diagnostic development 2022 sales: ~$90 million 26 IVD development programs either in pre-clinical or clinical phase • ~50% Pharma co- Offering both development revenues PCR and NGS technologies 20 C
Slide 48: Leveraging a comprehensive Liquid Biopsy portfolio
Leveraging a comprehensive Liquid Biopsy portfolio Diagnostic solutions Addressing opportunities in research and clinical applications to unlock insights from blood Liquid Non-Invasive Cancer Growing Biopsy Transplant market trends Prenatal research and monitoring applications Testing (NIPT) oncolog
Slide 49: Women's Health: Prenatal testing and detection of sexually transmitted diseases
Women’s Health: Prenatal Diagnostic solutions testing and detection of sexually transmitted diseases Cervical cancer screening Digene – Comprehensive range of human papillomavirus DNA test Maternal / Fetal testing AmniSure – For the detection of PAMG-1 in amniotic fluid of pregnant women PartoSure –
Slide 50: PCR / Nucleic Acid amplification
PCR / Nucleic Acid amplification Customers Digital PCR - QIAcuity PCR reagents and instrumentation Life Sciences Academic Pharma Applied testing Customized arrays Investor Resource Book 50
Slide 51: PCR: One of the most widely used tools in molecular biology
PCR: One of the most widely used tools in PCR / Nucleic acid amplification molecular biology What is polymerase chain reaction (PCR)? The process of replicating a specific DNA fragment though a series of thermal cycling to generate thousands to millions of copies. Unlimited customization of arrays t
Slide 52: Digital PCR: A new level of precision and sensitivity
Digital PCR: PCR / Nucleic acid amplification A new level of precision and sensitivity What is digital PCR? Digital PCR is a highly accurate approach for nucleic acid detection and quantification. The basic principle is the same as other PCR technologies Replicating a specific DNA fragment though a
Slide 53: Digital PCR: The latest generation of PCR technology
Digital PCR: The latest generation of PCR technology PCR / Nucleic acid amplification 1st generation 2nd generation 3rd generation Conventional PCR Quantitative RT-PCR (qPCR) Digital PCR (dPCR) Qualitative Relative quantification Absolute quantification Technically simple High accuracy, sensitivity
Slide 54: Leveraging novel technology with QIAcuity digital PCR
Leveraging novel technology with QIAcuity digital PCR PCR / Nucleic acid amplification Enabling access to the Easy-to-use comprehensive PCR market system vs. competition QIAcuity ~$400 million Differentiated nanoplate system QIAcuity One QIAcuity Four QIAcuity Eight Investor Resource Book 54
Slide 55: Five pillars: QIAcuity digital PCR continuing to expand applications
Five pillars: QIAcuity digital PCR continuing to expand applications > 1,000 cumulative placements by end of H1 2022 Highlighted applications Cancer Biopharma Microbial Wastewater Proteomics research detection testing New automated workflow 10 new kits and and custom New QIAGEN dPCR 70% of U.S. stat
Slide 56: PCR enzymes, reagents, and arrays for research workflows
PCR enzymes, reagents, and arrays PCR / Nucleic acid amplification for research workflows QuantiNova: Automatable, ultrafast kits QuantiNova: Automatable, ultrafast kits with in-process controlled safety measures with in-process controlled safety measures • PCR or 1-step & 2-step RT-PCR • Expert-des
Slide 57: Customized arrays: GeneGlobe design and analysis portal
Customized arrays: GeneGlobe design and analysis portal PCR / Nucleic acid amplification for biological content A world of genes, pathways and biological targets Find NGS, PCR and functional analysis assays in the relevant scientific context. Design custom products with full flexibility on target re
Slide 58: Genomics / NGS
Genomics / NGS Customers Universal NGS consumables Illumina collaboration NGS assays Life Sciences Academic Pharma Applied testing Molecular Diagnostics Bioinformatics solutions Investor Resource Book 58
Slide 59: Universal NGS: QIAseq solutions providing high-performance chemistry
Universal NGS: QIAseq solutions providing Genomics / NGS high-performance chemistry Target enrichment and streamlined library preparation leveraging leading sample preparation and bioinformatics QIAGEN NGS differentiation NGS research market Superior technology performance for target enrichment >$80
Slide 60: Partnership to accelerate use of NGS in clinical decision-making
Partnership to accelerate use of NGS Genomics / NGS in clinical decision-making QIAGEN to develop and market NGS IVD kits (including CDx assays) for use on Illumina systems • Integrated with QIAGEN sample technologies, NGS IVD kits and bioinformatics solutions for “Sample to Insight” experience • Ri
Slide 61: QIAGEN Digital Insights: Turning sequencing data into actionable information
QIAGEN Digital Insights: Turning Genomics / NGS sequencing data into clinically actionable information Bioinformatics [baɪ.oʊˌɪnfərˈmætɪks] is an interdisciplinary field that develops methods and software tools for understanding biological data. As an interdisciplinary field of science, bioinformati
Slide 62: The partner of choice for actionable insights from molecular and real-world data
The partner of choice for actionable insights Genomics / NGS from molecular and real-world data Multi-year partnership examples Preferred vendor for Deliver custom NGS Molecular oncology and Genomics England to patient data oncogenetic screening analyze 5 million interpretation for data in Japan’s l
Slide 63: Discovery Insights: Serving the research community
Discovery Insights: Serving the research community Genomics / NGS Example: Analyzing gene expression data from Sample to Insight Biological Freedom sample of Choice Sample Data to Information to Knowledge to data information knowledge to insight NGS library prep Normalization and QC Data Integration
Slide 64: Clinical Insights: Serving the diagnostic laboratories
Clinical Insights: Serving the diagnostic laboratories Genomics / NGS Software platform for scalable, standardized and reproducible variant interpretation VCF FASTQ Variant Variant alignment Variant assessment, Sequencing Final report and quality triage classification and control interpretation ONCO
Slide 65: Customer testimonial: Dr. Matthew Dodson
“The insights we gained through QIAGEN’s analysis point the way to a possible therapeutic target for disease intervention.” DR. MATTHEW DODSON Post-Doctoral Research Associate, Department of Pharmacology and Toxicology, University of Arizona Because of QIAGEN our customers are making improvements in
Slide 66: Sustainability at QIAGEN
Sustainability at QIAGEN Investor Resource Book 66
Slide 67: Our vision is aligned with building a sustainable business
Our vision is aligned with building a sustainable business Vision MAKING IMPROVEMENTS IN LIFE Identity POSSIBLE Mission Investor Resource Book 67
Slide 68: Our key levers: Sharpening our focus to optimize our impact
Our key levers: Sharpening our focus to optimize our impact Aligned with U.N. Sustainable Development Goals Environment Social Responsibility for the Serving society environment • Access to healthcare • Minimize carbon footprint • Quality and product safety • Reduce, recycle and • Customer satisfact
Slide 69: Environment
Environment Investor Resource Book 69
Slide 70: Environment: Reducing CO2e emissions across all operations
Environment: Reducing CO2e emissions across all operations Scope 1 and 2 Emissions Scope 3 Emissions 42% reduction by 2030 12.3% reduction by 2030 274k Scope 1 Combustion of fossil fuels Product Purchased Shipping disposal goods 11k Company Vehicles 10k QIAGEN 2021 Emissions Business Waste Scope 2 5
Slide 71: Environment: Integrating sustainability throughout the value chain
Environment: Integrating sustainability throughout the value chain Examples of sustainability in product design • Avoiding materials that cause a lot of damage when they are mined, cannot be recycled or do not decompose • Improving repairability, longevity, and allowing for reuse • Designing product
Slide 72: Social
Social Investor Resource Book 72
Slide 73: Social: Aiming to provide equitable access to all QIAGEN products
Social: Aiming to provide equitable access to all QIAGEN products Working to ensure developing countries gain access to affordable diagnostics to help prevent and treat diseases Areas of accelerated efforts Committed to expanding screening for tuberculosis (TB) in regions with high rates of disease
Slide 74: Deepening commitment to diversity and inclusion
Deepening commitment to diversity and inclusion Diverse teams strengthen our organization through the variety of ideas, perspectives and approaches Executive Council on Diversity and Strategic initiative to Equal Opportunity Inclusion increase gender (ECEO) Ambassador Program diversity Created to dr
Slide 75: Governance
Governance Investor Resource Book 75
Slide 76: Governance: QIAGEN operates under a two-tier corporate structure
Governance: QIAGEN operates under a two-tier corporate structure Investor Resource Book 76
Slide 77: Governance: International leadership team
Governance: International leadership team with over 200 years of combined industry experience Executive Committee Supervisory Board Chair Chief Executive Officer Chief Financial officer Lawrence A. Rosen Thierry Bernard Roland Sackers Joined 2013 Joined 2015 Joined 1999 Molecular Diagnostics Life Sc
Slide 78: Governance: Scientific Advisory Board
Governance: Scientific Advisory Board Members Dr. Peter Kaspar Dr. Neville Sanjana Prof. Dr. Ross Levine Leadership positions at Roche Core Faculty Member at the Diagnostics and bioMérieux New York Genome Center and Chair during career in diagnostics, Life Assistant Professor at New Sciences and pha
Slide 79: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Phone: +49 2103 29 11457 Q4 and FY 2023 results February 2024 Mobile: +49 152 018 11457 Q1 2024 results April 2024 E-mail: phoebe.loh@qiagen.com June 2024 Annual General Meeting Share information Alexandra Koenig Coordinator